Literature DB >> 10463364

Saccades and smooth pursuit in myotonic dystrophy.

S Shaunak1, R Orrell, L Henderson, C Kennard.   

Abstract

Reflexive saccades, remembered saccades, antisaccades, fixation and smooth pursuit were recorded in seven subjects with myotonic dystrophy (MD) and seven age-matched controls using the magnetic scleral search coil technique. Neuropsychological performance was assessed using the Wisconsin Card Sort Test and measures of verbal fluency. Subjects with MD showed significantly elevated error rates in the antisaccade and remembered saccade paradigms, consistent with prefrontal dysfunction, and these two measures of distractibility were significantly correlated with each other. Saccadic latencies, square wave jerk frequency, and smooth pursuit peak velocity gain showed no significant difference between the two groups, although the peak velocity of all classes of saccades was significantly reduced in patients with MD. These results extend the findings of previous studies of oculomotor function in MD, and provide novel evidence for a central contribution to abnormalities of eye movements in this condition.

Entities:  

Mesh:

Year:  1999        PMID: 10463364     DOI: 10.1007/s004150050411

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  3 in total

1.  Ocular motor myotonic phenomenon in myotonic dystrophy.

Authors:  M Versino; B Rossi; G Beltrami; G Sandrini; V Cosi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

2.  In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8.

Authors:  Dimitri Renard; Laurent Collombier; Christel Castelli; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Vincent Boudousq
Journal:  BMC Neurol       Date:  2016-07-13       Impact factor: 2.474

3.  Bilateral Adduction Palsy in a Patient with Myotonic Dystrophy Type 1.

Authors:  Hong-Jeon Kim; Jung-Hwan Oh; Sa-Yoon Kang
Journal:  Exp Neurobiol       Date:  2016-05-27       Impact factor: 3.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.